Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy

Journal of Pharmaceutical Sciences

Volumn 98, Issue 7, 2009, Pages 2317-2335

  Gulati, Abhishek ^a   Gerk, Phillip M ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporters; Active transport; Efflux pumps; Multidrug resistance transporters; Multidrug resistance associated proteins; P glycoprotein; Pharmacokinetics pharmacodynamics; Placenta; Pregnancy; Transporters

Indexed keywords

ABACAVIR; ABC TRANSPORTER; AMPRENAVIR; ATAZANAVIR; BREAST CANCER RESISTANCE PROTEIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; ELACRIDAR; EMTRICITABINE; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; LOPINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; NELFINAVIR; NEVIRAPINE; PLACENTA PROTEIN; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TIPRANAVIR; UNINDEXED DRUG; VALSPODAR; ZIDOVUDINE;

BCRP 1 GENE; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG TRANSPORT; GENE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HORMONAL REGULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE 1 GENE; MULTIDRUG RESISTANCE 2 GENE; MULTIDRUG RESISTANCE 4 GENE; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY; PREGNANT WOMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; REVIEW;

EID: 67650099989     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21623     Document Type: Review

References (102)

1. Syme MR, Paxton JW, Keelan JA. 2004. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 43:487-514. (Pubitemid 38858303)
2. Anderson GD. 2005. Pregnancy-induced changes in pharmacokinetics: Amechanistic-based approach. Clin Pharmacokinet 44:989-1008.
3. Loebstein R, Lalkin A, Koren G. 1997. Pharmacokinetic changes during pregnancy and their clinical relevance. Clin Pharmacokinet 33:328-343. (Pubitemid 27480937)
4. Srinivas RV, Middlemas D, Flynn P, Fridland A. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42: 3157-3162. (Pubitemid 28553735)
5. Evseenko D, Paxton JW, Keelan JA. 2006. Active transport across the human placenta: Impact on drug efficacy and toxicity. Expert Opin Drug Metab Toxicol 2:51-69. (Pubitemid 46100728)
6. Ceckova-Novotna M, Pavek P, Staud F. 2006. Pglycoprotein in the placenta: Expression, localization, regulation and function. Reprod Toxicol (Elmsford, NY) 22:400-410. (Pubitemid 44344445)
7. Pavek P, Staud F, Fendrich Z, Sklenarova H, Libra A, Novotna M, Kopecky M, Nobilis M, Semecky V. 2003. Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123. J Pharmacol Exp Ther 305:1239-1250. (Pubitemid 36618004)
8. Atkinson DE, Greenwood SL, Sibley CP, Glazier JD, Fairbairn LJ. 2003. Role of MDR1 and MRP1 in trophoblast cells, elucidated using retroviral gene transfer. Am J Physiol Cell Physiol 285: C584-C591. (Pubitemid 37022056)
9. Ushigome F, Takanaga H, Matsuo H, Yanai S, Tsukimori K, Nakano H, Uchiumi T, Nakamura T, Kuwano M, Ohtani H, Sawada Y. 2000. Human placental transport of vinblastine, vincristine, digoxin and progesterone: Contribution of P-glycoprotein. Eur J Pharmacol 408:1-10. (Pubitemid 30818136)
10. Utoguchi N, Chandorkar GA, Avery M, Audus KL. 2000. Functional expression of P-glycoprotein in primary cultures of human cytotrophoblasts and BeWo cells. Reprod Toxicol (Elmsford, NY) 14: 217-224. (Pubitemid 30415593)
11. Nagashige M, Ushigome F, Koyabu N, Hirata K, Kawabuchi M, Hirakawa T, Satoh S, Tsukimori K, Nakano H, Uchiumi T, Kuwano M, Ohtani H, Sawada Y. 2003. Basal membrane localization of MRP1 in human placental trophoblast. Placenta 24:951-958. (Pubitemid 37321810)
12. Patel P, Weerasekera N, Hitchins M, Boyd CA, Johnston DG, Williamson C. 2003. Semi quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, OATP-E and NTCP gene transcripts in 1st and 3rd trimester human placenta. Placenta 24:39-44. (Pubitemid 37184694)
13. Evseenko DA, Paxton JW, Keelan JA. 2006. ABC drug transporter expression and functional activity in trophoblast-like cell lines and differentiating primary trophoblast. Am J Physiol 290:R1357-R1365.
14. Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. 2006. Expression of the multidrug resistance P-glycoprotein, (ABCB1 glycoprotein) in the human placenta decreases with advancing gestation. Placenta 27:602-609.
15. Brangi M, Litman T, Ciotti M, Nishiyama K, Kohlhagen G, Takimoto C, Robey R, Pommier Y, Fojo T, Bates SE. 1999. Camptothecin resistance: Role of the ATP-binding cassette (ABC), mitoxantroneresistance half-transporter (MXR), and potential for glucuronidation in MXR-expressing cells. Cancer Res 59:5938-5946. (Pubitemid 30004955)
16. Mao Q, Unadkat JD. 2005. Role of the breast cancer resistance protein (ABCG2) in drug transport. AAPS J 7:E118-E133. (Pubitemid 41554295)
17. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. 2000. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 92:1651-1656. (Pubitemid 30807645)
18. St-Pierre MV, Serrano MA, Macias RI, Dubs U, Hoechli M, Lauper U, Meier PJ, Marin JJ. 2000. Expression of members of the multidrug resistance protein family in human term placenta. Am J Physiol 279:R1495-R1503. (Pubitemid 30953788)
19. Langmann T, Mauerer R, Zahn A, Moehle C, Probst M, Stremmel W, Schmitz G. 2003. Realtime reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin Chem 49:230-238. (Pubitemid 36143443)
20. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, Fridland A. 1999. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 5:1048-1051. (Pubitemid 29439577)
21. Meyer zu Schwabedissen HE, Grube M, Heydrich B, Linnemann K, Fusch C, Kroemer HK, Jedlitschky G. 2005. Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: Effects of gestational age and cellular differentiation. Am J Pathol 166: 39-48.
22. Novotna M, Libra A, Kopecky M, Pavek P, Fendrich Z, Semecky V, Staud F. 2004. P-glycoprotein expression and distribution in the rat placenta during pregnancy. Reprod Toxicol (Elmsford, NY) 18:785-792. (Pubitemid 38987965)
23. Kalabis GM, Kostaki A, Andrews MH, Petropoulos S, Gibb W, Matthews SG. 2005. Multidrug resistance phosphoglycoprotein (ABCB1) in the mouse placenta: Fetal protection. Biol Reprod 73:591-597. (Pubitemid 41356116)
24. Gil S, Saura R, Forestier F, Farinotti R. 2005. P-glycoprotein expression of the human placenta during pregnancy. Placenta 26:268-270. (Pubitemid 40247016)
25. Mathias AA, Hitti J, Unadkat JD. 2005. P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages. Am J Physiol 289:R963-R969. (Pubitemid 41397042)
26. Yeboah D, Sun M, Kingdom J, Baczyk D, Lye SJ, Matthews SG, Gibb W. 2006. Expression of breast cancer resistance protein (BCRP/ABCG2) in human placenta throughout gestation and at term before and after labor. Can J Physiol Pharmacol 84:1251-1258. (Pubitemid 46707373)
27. Meyer zu Schwabedissen HE, Grube M, Dreisbach A, Jedlitschky G, Meissner K, Linnemann K, Fusch C, Ritter CA, Volker U, Kroemer HK. 2006. Epidermal growth factor-mediated activation of the map kinase cascade results in altered expression and function of ABCG2 (BCRP). Drug Metab Dispos 34:524-533.
28. Mao Q. 2008. BCRP/ABCG2 in the placenta: Expression, function and regulation. Pharm Res 25:1244-1255.
29. Yasuda S, Itagaki S, Hirano T, Iseki K. 2005. Expression level of ABCG2 in the placenta decreases from the mid stage to the end of gestation. Biosci Biotechnol Biochem 69:1871-1876. (Pubitemid 41558850)
30. Wang H, Wu X, Hudkins K, Mikheev A, Zhang H, Gupta A, Unadkat JD, Mao Q. 2006. Expression of the breast cancer resistance protein (Bcrp1/Abcg2) in tissues from pregnant mice: Effects of pregnancy and correlations with nuclear receptors. Am J Physiol Endocrinol Metab 291:E1295-E1304. (Pubitemid 44904038)
31. Kalabis GM, Petropoulos S, Gibb W, Matthews SG. 2007. Breast cancer resistance protein (Bcrp1/ Abcg2) in mouse placenta and yolk sac: Ontogeny and its regulation by progesterone. Placenta 28: 1073-1081. (Pubitemid 47364540)
32. Meyer zu Schwabedissen HE, Jedlitschky G, Gratz M, Haenisch S, Linnemann K, Fusch C, Cascorbi I, Kroemer HK. 2005. Variable expression of MRP2 (ABCC2) in human placenta: Influence of gestational age and cellular differentiation. Drug Metab Dispos 33:896-904.
33. Evseenko DA, Paxton JW, Keelan JA. 2007. Independent regulation of apical and basolateral drug transporter expression and function in placental trophoblasts by cytokines, steroids, and growth factors. Drug Metab Dispos 35:595-601. (Pubitemid 46513262)
34. Yasuda S, Itagaki S, Hirano T, Iseki K. 2006. Effects of sex hormones on regulation of ABCG2 expression in the placental cell line BeWo. J Pharm Pharm Sci 9:133-139.
35. Wang H, Unadkat JD, Mao Q. 2008. Hormonal regulation of BCRP expression in human placental BeWo cells. Pharm Res 25:444-452. (Pubitemid 351257980)
36. Wang H, Lee EW, Zhou L, Leung PC, Ross DD, Unadkat JD, Mao Q. 2008. Progesterone receptor (PR) isoforms PRA and PRB differentially regulate expression of the breast cancer resistance protein in human placental choriocarcinoma BeWo cells. Mol Pharmacol 73:845-854.
37. Beringer PM, Slaughter RL. 2005. Transporters and their impact on drug disposition. Ann Pharmacother 39:1097-1108. (Pubitemid 40695979)
38. Tanabe M, Ieiri I, Nagata N, Inoue K, Ito S, Kanamori Y, Takahashi M, Kurata Y, Kigawa J, Higuchi S, Terakawa N, Otsubo K. 2001. Expression of P-glycoprotein in human placenta: Relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther 297: 1137-1143. (Pubitemid 32472514)
39. Hitzl M, Schaeffeler E, Hocher B, Slowinski T, Halle H, Eichelbaum M, Kaufmann P, Fritz P, Fromm MF, Schwab M. 2004. Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics 14:309-318. (Pubitemid 38638918)
40. Kobayashi D, Ieiri I, Hirota T, Takane H, Maegawa S, Kigawa J, Suzuki H, Nanba E, Oshimura M, Terakawa N, Otsubo K, Mine K, Sugiyama Y. 2005. Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab Dispos 33:94-101. (Pubitemid 40023519)
41. Conseil G, Deeley RG, Cole SP. 2005. Polymorphisms of MRP1 (ABCC1) and related ATP-dependent drug transporters. Pharmacogenet Genom 15:523-533. (Pubitemid 41044238)
42. Conrad S, Kauffmann HM, Ito K, Deeley RG, Cole SP, Schrenk D. 2001. Identification of human multidrug resistance protein 1 (MRP1) mutations and characterization of a G671V substitution. J Hum Genet 46:656-663. (Pubitemid 33134743)
43. Conrad S, Kauffmann HM, Ito K, Leslie EM, Deeley RG, Schrenk D, Cole SP. 2002. A naturally occurring mutation in MRP1 results in a selective decrease in organic anion transport and in increased doxorubicin resistance. Pharmacogenetics 12:321-330. (Pubitemid 34620660)
44. Leslie EM, Letourneau IJ, Deeley RG, Cole SP. 2003. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). Biochemistry 42:5214-5224. (Pubitemid 36560417)
45. Atkinson DE, Brice-Bennett S, D'Souza SW. 2007. Antiepileptic medication during pregnancy: Does fetal genotype affect outcome? Pediatr Res 62: 120-127.
46. Grohard P, Akbaraly JP, Saux MC, Gimenez S, Robert J, Brachet-Liermain A, Leng JJ. 1989. Transplacental passage of doxorubicin. J Gynecol Obstet Biol Reprod (Paris) 18:595-600.
47. Roboz J, Gleicher N, Wu K, Chanihian P, Kerenyi T, Holland J. 1979. Does doxorubicin cross the placenta? Lancet 2:1382-1383.
48. Derewlany LO, Leeder JS, Kumar R, Radde IC, Knie B, Koren G. 1991. The transport of digoxin across the perfused human placental lobule. J Pharmacol Exp Ther 256:1107-1111.
49. Holcberg G, Sapir O, Tsadkin M, Huleihel M, Lazer S, Katz M, Mazor M, Ben-Zvi Z. 2003. Lack of interaction of digoxin and P-glycoprotein inhibitors, quinidine and verapamil in human placenta in vitro. Eur J Obstet Gynecol Reprod Biol 109:133-137. (Pubitemid 36809119)
50. Ito S. 2001. Transplacental treatment of fetal tachycardia: Implications of drug transporting proteins in placenta. Semin Perinatol 25:196-201. (Pubitemid 32566001)
51. Schmolling J, Renke K, Richter O, Pfeiffer K, Schlebusch H, Holler T. 2000. Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate. Ther Drug Monit 22: 582-588. (Pubitemid 30744075)
52. Myllynen P, Pienimaki P, Vahakangas K. 2005. Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. Toxicol Appl Pharmacol 207:489-494. (Pubitemid 41265552)
53. Watts DH. 2006. Treating HIV during pregnancy: An update on safety issues. Drug Saf 29:467-490. (Pubitemid 43855080)
54. Marzolini C, Kim RB. 2005. Placental transfer of antiretroviral drugs. Clin Pharmacol Ther 78:118-122.
55. Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH, Schinkel AH. 2001. P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol 59:806-813. (Pubitemid 32274009)
56. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. 1998. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol (Elmsford, NY) 12:457-463. (Pubitemid 29110878)
57. Smit JW, Huisman MT, van Tellingen O, Wiltshire HR, Schinkel AH. 1999. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 104:1441-1447.
58. Molsa M, Heikkinen T, Hakkola J, Hakala K, Wallerman O, Wadelius M, Wadelius C, Laine K. 2005. Functional role of P-glycoprotein in the human blood-placental barrier. Clin Pharmacol Ther 78:123-131. (Pubitemid 41112280)
59. Choo EF, Leake B, Wandel C, Imamura H, Wood AJ, Wilkinson GR, Kim RB. 2000. Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metab Dispos 28:655-660. (Pubitemid 30390404)
60. Gutmann H, Fricker G, Drewe J, Toeroek M, Miller DS. 1999. Interactions of HIV protease inhibitors with ATP-dependent drug export proteins. Mol Pharmacol 56:383-389. (Pubitemid 29347615)
61. Miller DS, Nobmann SN, Gutmann H, Toeroek M, Drewe J, Fricker G. 2000. Xenobiotic transport across isolated brain microvessels studied by confocal microscopy. Mol Pharmacol 58:1357-1367.
62. Profit L, Eagling VA, Back DJ. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS (London, England) 13:1623-1627. (Pubitemid 30015708)
63. Washington CB, Wiltshire HR, Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062. (Pubitemid 30660360)
64. Drewe J, Gutmann H, Fricker G, Torok M, Beglinger C, Huwyler J. 1999. HIV protease inhibitor ritonavir: A more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol 57:1147-1152. (Pubitemid 29171690)
65. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. 2008. Inhibition of placental Pglycoprotein: Impact on indinavir transfer to the foetus. Br J Clin Pharmacol 65:667-673.
66. Huisman MT, Smit JW, Crommentuyn KM, Zelcer N, Wiltshire HR, Beijnen JH, Schinkel AH. 2002. Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301. (Pubitemid 35449015)
67. Vishnuvardhan D, Moltke LL, Richert C, Greenblatt DJ. 2003. Lopinavir: Acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. AIDS (London, England) 17:1092-1094. (Pubitemid 36549726)
68. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, Haefeli WE, Efferth T. 2007. Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-245. (Pubitemid 47072063)
69. Gupta A, Zhang Y, Unadkat JD, Mao Q. 2004. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 310:334-341. (Pubitemid 38812728)
70. Olson DP, Scadden DT, D'Aquila RT, De Pasquale MP. 2002. The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1). AIDS (London, England) 16:1743-1747.
71. Chappuy H, Treluyer JM, Rey E, Dimet J, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal- fetal transfer and amniotic fluid accumulation of protease inhibitors in pregnant women who are infected with human immunodeficiency virus. Am J Obstet Gynecol 191:558-562. (Pubitemid 39178714)
72. Marzolini C, Rudin C, Decosterd LA, Telenti A, Schreyer A, Biollaz J, Buclin T. 2002. Transplacental passage of protease inhibitors at delivery. AIDS (London, England) 16:889-893. (Pubitemid 34409012)
73. Chappuy H, Treluyer JM, Jullien V, Dimet J, Rey E, Fouche M, Firtion G, Pons G, Mandelbrot L. 2004. Maternal-fetal transfer and amniotic fluid accumulation of nucleoside analogue reverse transcriptase inhibitors in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 48:4332-4336. (Pubitemid 39434895)
74. Mandelbrot L, Peytavin G, Firtion G, Farinotti R. 2001. Maternal-fetal transfer and amniotic fluid accumulation of lamivudine in human immunode- ficiency virus-infected pregnant women. Am J Obstet Gynecol 184:153-158. (Pubitemid 32141658)
75. Moodley J, Moodley D, Pillay K, Coovadia H, Saba J, van Leeuwen R, Goodwin C, Harrigan PR, Moore KH, Stone C, Plumb R, Johnson MA. 1998. Pharmacokinetics and antiretroviral activity of lamivudine alone or when coadministered with zidovudine in human immunodeficiency virus type 1-infected pregnant women and their offspring. J Infect Dis 178:1327-1333. (Pubitemid 28523269)
76. Watts DH, Brown ZA, Tartaglione T, Burchett SK, Opheim K, Coombs R, Corey L. 1991. Pharmacokinetic disposition of zidovudine during pregnancy. J Infect Dis 163:226-232.
77. Mirochnick M, Dorenbaum A, Holland D, Cunningham-Schrader B, Cunningham C, Gelber R, Mofenson L, Culnane M, Connor J, Sullivan JL. 2002. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 21:835-838.
78. van Heeswijk RP, Khaliq Y, Gallicano KD, Bourbeau M, Seguin I, Phillips EJ, Cameron DW. 2004. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 76:588-597. (Pubitemid 39601548)
79. Acosta EP, Zorrilla C, Van Dyke R, Bardeguez A, Smith E, Hughes M, Huang S, Pitt J, Watts H, Mofenson L. 2001. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2:460-465. (Pubitemid 33138710)
80. Unadkat JD, Wara DW, Hughes MD, Mathias AA, Holland DT, Paul ME, Connor J, Huang S, Nguyen BY, Watts DH, Mofenson LM, Smith E, Deutsch P, Kaiser KA, Tuomala RE. 2007. Pharmacokinetics and safety of indinavir in human immunodefi- ciency virus-infected pregnant women. Antimicrob Agents Chemother 51:783-786. (Pubitemid 46185308)
81. Mathias AA, Maggio-Price L, Lai Y, Gupta A, Unadkat JD. 2006. Changes in pharmacokinetics of anti-HIV protease inhibitors during pregnancy: The role of CYP3A and P-glycoprotein. J Pharmacol Exp Ther 316:1202-1209. (Pubitemid 43345295)
82. Krauer B, Dayer P, Anner R. 1984. Changes in serum albumin and alpha 1-acid glycoprotein concentrations during pregnancy: An analysis of fetal-maternal pairs. Br J Obstet Gynaecol 91: 875-881. (Pubitemid 14033846)
83. Sudhakaran S, Ghabrial H, Nation RL, Kong DC, Gude NM, Angus PW, Rayner CR. 2005. Differential bidirectional transfer of indinavir in the isolated perfused human placenta. Antimicrob Agents Chemother 49:1023-1028. (Pubitemid 40327719)
84. Bawdon RE. 1998. The ex vivo human placental transfer of the anti-HIV nucleoside inhibitor abacavir and the protease inhibitor amprenavir. Infect Dis Obstet Gynecol 6:244-246. (Pubitemid 29066601)
85. Forestier F, de Renty P, Peytavin G, Dohin E, Farinotti R, Mandelbrot L. 2001. Maternal-fetal transfer of saquinavir studied in the ex vivo placental perfusion model. Am J Obstet Gynecol 185: 178-181. (Pubitemid 32681815)
86. Gavard L, Gil S, Peytavin G, Ceccaldi PF, Ferreira C, Farinotti R, Mandelbrot L. 2006. Placental transfer of lopinavir/ritonavir in the ex vivo human cotyledon perfusion model. Am J Obstet Gynecol 195:296-301. (Pubitemid 43927527)
87. Casey BM, Bawdon RE. 1998. Placental transfer of ritonavir with zidovudine in the ex vivo placental perfusion model. Am J Obstet Gynecol 179:758-761. (Pubitemid 28447260)
88. Sudhakaran S, Rayner CR, Li J, Kong DC, Gude NM, Nation RL. 2006. Differential protein binding of indinavir and saquinavir in matched maternal and umbilical cord plasma. Br J Clin Pharmacol 63:315-321. (Pubitemid 46257074)
89. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A. 2002. Response to antiretroviral treatment in HIV-1- infected individuals with allelic variants of the multidrug resistance transporter 1: A pharmacogenetics study. Lancet 359:30-36. (Pubitemid 34119193)
90. Schaeffeler E, Eichelbaum M, Brinkmann U, Penger A, Asante-Poku S, Zanger UM, Schwab M. 2001. Frequency of C3435T polymorphism of MDR1 gene in African people. Lancet 358:383-384. (Pubitemid 32739101)
91. Chandler B, Almond L, Ford J, Owen A, Hoggard P, Khoo S, Back D. 2003. The effects of protease inhibitors and nonnucleoside reverse transcriptase inhibitors on p-glycoprotein expression in peripheral blood mononuclear cells in vitro. J Acquir Immune Defic Syndr 1999. 33:551-556. (Pubitemid 36975841)
92. Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD. 2007. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 8:227-235. (Pubitemid 46477734)
93. Woodahl EL, Yang Z, Bui T, Shen DD, Ho RJ. 2005. MDR1 G1199A polymorphism alters permeability of HIV protease inhibitors across P-glycoprotein-expressing epithelial cells. AIDS (London, England) 19:1617-1625. (Pubitemid 41502674)
94. Solas C, Simon N, Drogoul MP, Quaranta S, Frixon-Marin V, Bourgarel-Rey V, Brunet C, Gastaut JA, Durand A, Lacarelle B, Poizot-Martin I. 2007. Minimal effect of MDR1 and CYP3A5 genetic polymorphisms on the pharmacokinetics of indinavir in HIV-infected patients. Br J Clin Pharmacol 64:353-362. (Pubitemid 47283866)
95. Colombo S, Soranzo N, Rotger M, Sprenger R, Bleiber G, Furrer H, Buclin T, Goldstein D, Decosterd L, Telenti A. 2005. Influence of ABCB1, ABCC1, ABCC2, and ABCG2 haplotypes on the cellular exposure of nelfinavir in vivo. Pharmacogenet Genom 15:599-608. (Pubitemid 41113333)
96. Anderson PL, Lamba J, Aquilante CL, Schuetz E, Fletcher CV. 2006. Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: A pilot study. J Acquir Immune Defic Syndr 1999. 42:441-449. (Pubitemid 44050891)
97. Kruse G, Staszewski S, Cascorbi I, Breske A, Moecklinghoff C, Stocker H. 2003. Mutations in the drug transporter genes MDR1 and MRP2 and pharmacokinetics in patients treated with saquinavir/lopinavir. 4th International Workshop on Clinical Pharmacology of HIV Therapy, ed., Cannes, France.
98. Acosta EP, Henry K, Baken L, Page LM, Fletcher CV. 1999. Indinavir concentrations and antiviral effect. Pharmacotherapy 19:708-712.
99. Acosta EP, Nachman S, Wiznia A, Turner M, Sommadossi JP, Yogev R. 2000. Pharmacokinetic (PK) Evaluation of Nelfinavir (NFV) in Combination with Nevirapine (NVP) or Ritonavir (RTV) in HIV-Infected Children - PACTG 403. Intersci Conf Antimicrob Agents Chemother ed., Univ. of Alabama at Birmingham, Birmingham, AL.
100. Montaner JS, Schutz M, Schwartz R, Jayaweera DT, Burnside AF, Walmsley S, Saag MS. 2006. Efficacy, safety and pharmacokinetics of oncedaily saquinavir soft-gelatin capsule/ritonavir in antiretroviral-naive, HIV-infected patients. Med Gen Med 8:36. (Pubitemid 43756902)
101. Langmann P, Zilly M, Weissbrich B, Schlor C, Vath T, Richter E, Klinker H. 2000. Therapeutic drug monitoring of saquinavir in patients during protease inhibitor therapy with saquinavir alone or in combination with ritonavir or nelfinavir. Eur J Med Res 5:59-62.
102. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF. 2008. Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 38:1330-1339.